Sensitization of Cancer Cells to Immunoconjugate-Induced Cell Death by Transfection with Interleukin-13 Receptor Alpha-Chain
Description of Invention:
The claimed technology relates to the use of gene transfer techniques to sensitize cancer cells to IL-13 Receptor-mediated immunotoxin induced cell death. Specifically, the inventor has shown that stable gene transfer of the IL-13Ralpha2 chain, of the IL-13 receptor, significantly sensitizes cancer cells to the effects of IL-13 toxin by approximately 520-1000-fold. Since many cancers, e.g., brain, breast, lung, head and neck, pancreatic, prostate or liver, can be inoperable, direct intratumoral administration of treatment-agents may become necessary. As such, the claimed invention shows that a combination approach, utilizing both gene transfer and systemic or locoregional cytotoxin therapy, may be available as a new potent treatment regimen for intractable or refractory cancers.
Inventors:
R. Puri (FDA)
Patent Status:
DHHS Reference No. E-032-00/1 filed 31 August 2000
Related Technologies:
DHHS Reference No. E-032-00/2 filed 10 Nov 2000, "Modulating IL-13 Activity Using Mutated IL-13 Molecules That Are Antagonists or Agonists of IL-13"
Portfolios: Gene Based Therapies Cancer
Cancer -Therapeutics Gene Based Therapies -Therapeutics
For Additional Information Please Contact: Brenda Hefti Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4632
Email: heftib@mail.nih.gov
Fax: (301) 402-0220
